Skip to content

Evaluation of the Impact of the HL Natural, Inc. Tension Relief Product

Evaluation of the Impact of the HL Natural, Inc. Tension Relief Product on the Reduction of Symptoms in Adults Who Suffer From Mild to Moderate Tension Headaches

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04091555
Enrollment
117
Registered
2019-09-17
Start date
2019-10-16
Completion date
2020-09-16
Last updated
2021-11-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Headache, Tension

Brief summary

The primary hypothesis of the present study is that supplementation with the Tension Relief test product will reduce the severity of symptoms of a tension headache.

Detailed description

Patients will begin taking the capsules at the onset of headache symptoms. Onset is defined as the point in time the participant feels that it is necessary to take the test product for relief of symptoms. When the participant decides to take the test product, they will report symptoms in the headache diary prior to taking the product and rate their symptoms on a 10-point Mankoski scale. After consuming the product, the participant will complete a Mankoski scale at 15 minutes, 30 minutes and 1 hour after taking the product. If needed the participant will be allowed to take alternative medication (alternative treatment) after an hour after taking the product. If alternative medication is taken, the participant will record this in their headache diary.

Interventions

DIETARY_SUPPLEMENTHLNatural Tension

Understand the impact of the supplement on Tension Headaches

Sponsors

HLNatural, Inc.
CollaboratorINDUSTRY
Hawthorne Effect Inc.
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

Adult candidates who are in overall good health and who suffer from mild to moderate tension headaches. Participants will be deemed to be in good health if they do not report any of the existing medical conditions asked about in the screening questionnaire.

Exclusion criteria

* Those who have been diagnosed with migraine headaches. * Those who score between 36-49 or 60-78 on screening questionnaire. * Is \< 18 years of age * Those who have been diagnosed with fibromyalgia. * Women that are pregnant or breastfeeding. * Alcohol consumption more than 7 drinks per week or more than 3 drinks per occasion. * Routine recreational drug use such as marijuana. * Chronic renal disease * Chronic liver disease * Allergy to any of the following: Aspirin or any other product including Salicylates, Boswellia, Feverfew, Skullcap, White Willow Bark, Rice Hull, or Vegetable Cellulose. * Unable to swallow pills. * Unwilling to try test product for relief of pain and tension headache symptoms. * Participants who are currently taking any anticoagulation medications daily. (Aspirin, Warfarin, Heparin etc.)

Design outcomes

Primary

MeasureTime frameDescription
The Evaluation of the Impact of HLNatural Tension Relief Product for Adults who Suffer from Mild to Moderate Tension HeadachesAfter taking the test product, the participant will complete a Mankoski pain scale at 15 minutes after the start of the event, 30 minutes after the start of the event, and 1 hour after the start of the event.Those subjects who meet the inclusion/exclusion criteria will be invited to be part of the study. The subject will sign consent and complete the required surgery and questionnaires before taking the test product. • At the onset of the headache, the participant will start a Headache Diary and complete a 10-point Mankoski pain scale. • After completing the surveys, the participant will take test product. The participant will take 2 capsules with 6-8 oz. of water per headache episode. With a max of 6 pills per day.

Secondary

MeasureTime frameDescription
Understanding If HLNatural impacts the Intensity of Tension Headaches. Headaches.another interventionStubjects will be evaluated for up to 60 days or 3 episodes of a headacheA diary will be kept of the intensity and need for other intervention during each episode.
Outcome of all Adverse Events while consuming HLNatural SuppliementAll adverse events will be captured throughout the 60 days or after 3 episodes of headaches or until the subject exits the trial.Throughout the study the subject will capture any adverse events that have occurred. All events will recorded in the subject's diary.
Outcome of Subjects Natural Behavior During the Clinical Trial10-point Mankoski Scale and Headache Diary will be at the start of the headache, 15 minutes after start of the event, 30 minutes after start of event and 60 minutes after the start of the event. The activity will be repeated for up to 3 events.Before the test product is taken the subject will complete a screening, demographic and baseline survey. At the end of the survey the researchers will use what is in the literature to help establish normal behavior. Upon completion of the study the participant will complete an exit study. The surveys and questionnaires will be used to establish normal behavior of the subject.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026